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The recent understanding of the molecular basis of T cell recogni-
tion of human tumours has allowed for the development of vaccine
trials targeting the induction of antigen-specific, tumour-reactive
CD8+ CTL. In some cases, CTL reactive against defined tumour
epitopes may mediate tumour regression (Kawakami et al, 1998).
Many limitations must be overcome in order to achieve optimal
efficacy for anti-tumour CTL in vivo, including the identification
of means by which to increase antigen-specific CTL numbers,
targeting these T cells to the sites of tumour, maintaining T cell
viability and function in the potentially immunosuppressive
tumour microenvironment, and promoting increased infiltration of
tumours by additional immune cells (i.e., NK cells, dendritic cells
(DC), macrophages, PMN). Clearly, CD4+ T cell responses may
directly impact each of these issues by potentiating both the
afferent and efferent aspects of CD8+ T cell function, and by
mediating Th1-type DTH reactions within tumour sites, thereby
promoting pro-inflammatory cytokine and/or chemokine produc-
tion (Grohman et al, 1998; Topalian et al, 1996; Bour et al, 1998).
Cytokines may enhance locoregional vascular permeability and
increase cellular expression of MHC-peptide complexes, thus,
improving antitumour T cell efficacy in situ. Chemokines (i.e.
IFN-γ dependent IP-10 and Mig) may facilitate lymphocyte infiltra-
tion and promote the involution of the tumour-associated neovas-
cular bed (Tannebaum et al, 1998; Sgadari et al, 1996). Furthermore,
CD4+ T cells may mediate direct antitumour immunity (Ossendorp
et al, 1998) and Th1-type CD4+ T cell responses appear crucial to
productive antitumour immune responses (Bour et al, 1998; Aruga
et al, 1997; Halliday et al, 1995). 
Despite the importance of antitumour CD4+ T cells, tumour
antigen-derived peptides that serve as CD4+ T cell epitopes have
rarely been defined (Topalian et al, 1996; Storkus and Zarour,
2000). In the present study, we have focused our attention on
CD4+ T cell responses restricted by HLA-DR4, in part due to the
large information base for this prototype MHC class II allele and
its associated peptide-binding preference, as well as, the potential
increased risk factor for DR4+ individuals to develop certain
forms of cancer (i.e. melanoma, gastric carcinoma, basal cell
carcinoma (Barger et al, 1982); Ogoshi et al, 1994; Czarnecki et al,
1993). We have identified novel peptide sequences derived from
the gp100/pmel17 and tyrosinase melanoma-associated antigens
that elicit IFN-γ production from CD4+ Th1-type T cells obtained
directly from the PBMC of HLA-DR4+ melanoma patients and
from cultured CD4+ T cells derived from normal HLA-DR4+
donors stimulated in vitro with dendritic cell-based ‘vaccines’. We
anticipate that constitutive or induced CD4+ T cell responses
directed against these epitopes in HLA-DR4+ melanoma patients
may preclude recurrence or mediate the regression of disease,
respectively. 
MATERIALS AND METHODS 
Cell lines and media 
The T2.DR4 (DRB1*0401+) cell line (kindly provided by
Dr Janice Blum, Indiana University School of Medicine,
Indianapolis, IN) was used as antigen-presenting cell line in these
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studies. This cell line uniformly expresses HLA-DR*0401 mole-
cules that contain moderate-to-low affinity binding peptides
derived mainly from intracellular invariant chain (CLIP, class
II-associated invariant chain peptide) due to a genetic deficiency
in HLA-DM (Turvy and Blum, 1998). Melanoma cell lines (Mel
526 (HLA-DR4-negative, gp100/pmel17+, tyrosinase+), MEL-
SLM2 (HLA-DR4+, gp100/pmel17+, tyrosinase+), M21 (HLA-
DR4-dim+, gp100/pmel17+, tyrosinase+), COLO38 (HLA-DR4+,
gp100/pmel17+, tyrosinase+) and MEL1011 (HLA-DR4+, gp100/
pmel17+/–, tyrosinase+)) were passaged 1:2–1:10 using trypsin-
EDTA (GIBCO/Life Technologies, Grand Island, New York)
when confluent. All cell lines were maintained in RPMI-1640
supplemented with 10% heat-inactivated fetal bovine serum, 100
IU/ml penicillin, 100 ug/ml streptomycin, and 10 mM L-glutamine
(all reagents GIBCO). Mel 526 was the gift of Dr Steven
Rosenberg (National Cancer Institute, NCI, Bethesda, MD),
MEL1011 was the kind gift of Dr Suzanne Topalian (NCI) and
M21 and COLO38 were the kind gifts of Dr Soldano Ferrone
(Roswell-Park Cancer Institute, Buffalo, NY). SLM2 was gener-
ated at the University of Pittsburgh. 
Peptide selection and synthesis 
The protein sequences of the melanoma associated antigens gp
100/pmel17 and tyrosinase were obtained from GENBANK and
analysed for HLA-DR*0401 binding peptides using a neural
network algorithm (Honeyman et al, 1998). High scoring nine
amino acid long sequences were typically extended by three amino
acids on either flank using the genomic corresponding sequences.
Alternatively, if high scoring nine amino acid long sequences were
found to overlap, the longer overlapping sequences were synthe-
sized, with amino acid extensions added to the end(s) of putative
DR4-binding sequence(s). Overall, peptides were 15–23 amino
acids in length (Table 1) and were synthesized by FMOC chem-
istry by the University of Pittsburgh Cancer Institute’s (UPCI)
Peptide Synthesis Facility (Shared Resource). Peptides were
>90% pure based on HPLC profile and MS/MS mass spectro-
metric analysis performed by the UPCI Protein Sequencing
Facility (Shared Resource). 
Peptide-binding assay 
The peptide-binding determinations were performed using a
solid-state competitive-binding assay as previously described
(Southwood et al, 1998). 
Isolation of patient and normal donor PBMC-Derived 
T cells 
Forty-to-one hundred ml of patient or normal donor heparinized
blood was obtained with informed consent under an IRB-approved
protocol and diluted 1:2 with HBSS, applied to ficoll-hypaque
gradients (LSM, Organon-Teknika, Durham, NC) per the manu-
facturer’s instructions, and centrifuged at 550 × g for 25 min at RT.
Patient and normal donor information is provided in Table 2.
Lymphocytes at the buoyant interface were recovered and washed
Table 1 gp100 and tyrosinase peptides analysed in this study: algorithm scores, solid-state binding IC50 values, and summary of CD4+ T cell responsiveness
in IFN- γ ELISPOT assays 
Algorithm
Binding affinity (IC50) T cell responses evaluated in 
DRB1*0401 binding DRB1 DRB1 MEL-NED MEL ND-IVS 
Peptide Sequence score (1st AA position no.) *0401 *0404 (of 11)a (of 5)b (of 10)c
gp100/pmel176–26 KRCLLHLAVIGALLAVGATKV 4 (15); 5 (9); 6 (12) – 335 7 1 7
gp100/pmel1744–59** WNRQLYPEWTEAQRLD 4 (48) 136 514 8 1 9
gp100/pmel17150–168 VYVWKTWGQYWQVLGGPVS 4 (150); 6 (161) –– 00 0  
gp100/pmel17167–189 VSGLSIGTGRAMLGTHTMEVTVY 3 (170); 4 (178) – 372 0 0 0 
gp100/pmel17283–304 PGPVTAQVVLQAAIPLTSCGSS 4 (292); 6 (286) 2893 51 0 0 0 
gp100/pmel17377–398 EKVPVSEVMGTTLAEMSTPEAT 4 (385); 10 (389) 7014 92 0 0 0 
gp100/pmel17400–421 MTPAEVSIVVLSGTTAAQVTTT 3 (400); 4 (407); 5 (408,409) 148 17 0 0 0 
gp100/pmel17506–522 EGDAFELTVSCQGGLPK 6 (510) 3210 3553 0 0 0 
gp100/pmel17540–561 LCQPVLPSPACQLVLHQILKGG 3 (552); 5 (544) – 614 0 0 0 
gp100599–619/pmel17606–626 IVGILLVLMAVVLASLIYRRR 4 (600,607); 5 (603,604,605) –– 00 0  
gp100615–633/pmel17622–640 IYRRRLMKQDFSVPQLPHS 4 (615,625); 7 (621) 51 9 8 0 9
tyrosinase56–70** QNILLSNAPLGPQFP 4 (59); 5 (58) 5441 178 7 0 8
tyrosinase80–95 WPSVFYNRTCQCSGNF 3 (80,85); 5 (84); 10(83) –– 00 0  
tyrosinase156–175 YGQMKNGSTPMFNDINIYDL 4 (156); 5 (166); 10(159) 1387 953 7 0 6
tyrosinase178–194 WMHYYVSMDALLGGSEI 6 (181); 8 (182) NT NT 1 1 3
tyrosinase365–381D ALHIYMDGTMSQVQGSA 8 (368) 17 31 6 2 9
tyrosinase365–381N ALHIYMNGTMSQVQGSA 4 (368) 1744 174 3 2 4
tyrosinase448–462** DYSYLQDSDPDSFQD 3 (449); 6 (451) 1684 – 00 0  
aNumber of HLA-DR4+ melanoma patients (of 11, no evidence of disease (NED) at time of assessment) with freshly- isolated CD4+ T cell reactivity against the
indicated peptide as monitored in IFN-γ ELISPOT assays. bNumber of HLA-DR4+ melanoma patients (of 5, with active disease) with freshly-isolated CD4+ T cell
reactivity against the indicated peptide as monitored in IFN- γ ELISPOT assays. cNumber of normal HLA- DR4+ donors (of 10 evaluated) with CD4+ T cells
responding against the indicated peptide in IFN-γ ELISPOT assays after 2 rounds of in vitro stimulation (IVS) with autologous dendritic cells pulsed with peptide.
No normal donors displayed significant CD4+ T cell reactivity against any of these peptides prior to in vitro stimulation (see Figure 1C). Patients were considered
positive responders if their calculated frequency of peptide-specific spots exceeded the mean + 3 standard deviation values (see Figure 1 legend) obtained from
10 normal HLA-DR4+ donors against that indicated peptide. Known CTL epitopes embedded in these sequences are indicated by shading, while positive T cell
responses are in bold and underlined (Kittlesen et al, 1998; Skipper et al, 1996; Ranieri et al, 2000; Brinckerhoff et al, 2000). Peptides indicated with ** represent
previously identified HLA-DR4- presented epitopes. Binding data is reported as IC50 in nM and represents the concentration of the indicated peptide to block 50%
of the binding of a radio-labeled reference peptide to purified HLA-DR4 complexes. IC50 values ≥ 10 000 nM are indicated as–. NT = Not Tested. 1740 LS Kierstead et al
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twice with HBSS to remove residual platelets and ficoll-hypaque.
Cells were frozen in 90% FCS containing 10% DMSO (Sigma
Chemical Co., St Louis, MO) at 107 lymphocytes/vial using
controlled-rate freezing technique. On the day of ELISPOT assay,
cells were thawed and washed twice with HBSS. CD4+ T cells
were first isolated using MACS™ (Miltenyi) anti-human CD4
beads and MiniMACS™ columns per the manufacturer’s protocol.
CD4+ T cell yields were typically 25–35% of starting PBMC
numbers loaded, with purity exceeding 97% as assessed by flow
cytometry. 
Induction of antitumour T effector lymphocytes 
Autologous dendritic cells (107) were prepared as previously
described by 7-day culture of plastic-adherent PBMC in GM-CSF
and IL-4 (Tueting et al, 1998). Harvested, non-adherent DC were
then loaded with antigen in one of three ways. DC were either: (1)
pulsed with 10 uM synthetic peptides for 3–4 h at 37˚C; (2) pulsed
with 250 µ g/ml Mel 526 (gp100/pmel17+ tyrosinase+) lysate for
24 h at 37˚C; or (3) infected with recombinant vaccinia virus
encoding the gp100/pmel17 or tyrosinase antigens (Kittlesen et al,
1998) at an MOI of 50 for 24 h at 37˚C. The resulting ‘antigen-
loaded’ DC were washed, irradiated (3000 rad) and used to stimu-
late purified CD4+ T cells at a 50:1 responder-to-stimulator ratio.
Primary in vitro cultures were performed in AIM-V medium
containing 5% HuAB serum and 1 ng/ml of both rhIL-1 and rhIL-
7 (Genzyme). Cultures were restimulated with the residual 1/2 of
the DC-tumour stimulator preparation (cryopreserved for 1 week)
on day 7 in AIM-V medium containing 5% HuAB serum and
10 IU/ml rhIL-2 (kind gift of Chiron Corporation, Emeryville,
CA). These stimulated T cells were harvested on day 14–17 and
analyzed for peptide/tumour specificity in ELISPOT assays. 
IFN-γ ELISPOT and capture of peptide-reactive CD4+ T
cells 
ELISPOT was performed essentially as previously described (Herr
et al, 1998). Spots were imaged using the Zeiss AutoImager and
statistical comparisons determined using a Student’s two-tailed
t-test analysis. The data are represented as IFN-γ spots per 100 000
CD4+ T cells analysed. HLA-restriction of CD4+ T cell responses
was demonstrated by addition of blocking mAb (5 ug/well)
directed against HLA-DR4 (clone 359-13F10, IgG, kindly
provided by Dr Janice Blum, Indiana University School of
Medicine, Indianapolis, IN). 
PCR analysis 
PCR analyses were performed to determine patient HLA-DR4
genotype using a commercial PCR panel according to the manu-
facturer’s instructions (Dynal, Oslo, Norway). RT-PCR analysis
was also used to determine tumor expression of gp100/pmel17 and
tyrosinase mRNA (Storkus and Zarour, 2000). 
RESULTS 
Selection and screening of candidate DR4-binding
peptides derived from gp100/pmel17 and tyrosinase 
In order to identify a series of candidate peptides capable of being
recognized by CD4+ T cells in HLA-DRA+ patients who have, or
have had melanoma, we subjected the cDNA sequences of
gp100/pmel17 and tyrosinase to analysis using a computer algo-
rithm designed to predict HLA-DR*0401-binding peptides
(Honeyman et al, 1998). Nine amino acid-long ‘core’ sequences
were evaluated and scored from 0–10, with the highest scoring
sequences taken to represent peptides most likely to bind to HLA-
DR*0401. A total of 18 peptides were produced (Table 1). One
gp100/pmel17 (gp100/pmel1744–59) and two tyrosinase peptides
(tyrosinase56–70 and tyrosinase448–462), previously identified to be
recognized by DR4-restricted CD4+ TIL (Storkus and Zarour,
2000), were included as ‘positive controls’ among the panel used
in this study. Based on the predictive algorithm used, these
‘control’ peptides would have been produced for analysis due to
their inclusion of core epitopes yielding algorithm scores ≥ 4
(Table 1). 
Table 2 HLA-DR4+ patients evaluated in this study 
Tumour antigen
Status at time DR4 expression (RT-PCR) 
Patient Age Sex Stage Treatment of evaluation genotype gp100 tyrosinase 
SLM1 71 F IV S, DC/peptide NED, 1.5 *0401 + + 
SLM2 64 F IV S, IFN-α NED, 5.0 *0401 + +/– 
SLM3 43 M I S, IFN-α NED, 3.5 *0408 NA NA 
SLM4 57 M IV S, IFN-α NED, 3.3 *0404 + + 
SLM5 34 M IV S, IFN-α NED, 4.1 *04X NA NA 
SLM6 37 F I S, IFN-α NED, 1.9 *0401 NA NA 
SLM7 46 M I S NED, 2.3 *0404 NA NA 
SLM8 49 M II S NED, 4.0 *0404 + + 
SLM9 35 F III S,C,R NED, 0.3 *0401 + – 
SLM10 74 M IV S NED, 0.4 *0401 NA NA 
SLM11 58 M IV S NED, 0.3 *0404 NA NA 
SLM12† 39 F IV S,C,IFN-α Stable *0401 NA NA 
SLM13 71 M IV None Mets, Liver/lung *0401 NA NA 
SLM14 52 M IV C Mets, Brain *0408 NA NA 
SLM15 66 M IV S, IFN-α Mets, Liver/lung *0402 NA NA 
SLM16 64 M IV None Mets, Liver/lung *0401 NA NA 
Abbreviations Used: C, Chemotherapy; R, Radiotherapy; S, Surgery; DC/peptide, Dendritic Cell + Synthetic Melanoma Peptide
Vaccine; IFN-α , Interferon Alpha Therapy; NED, No evidence of Disease at time of Blood Draw, NA, Not Available for
Evaluation. Patient SLM5 genotyped as HLA-DR4 of indeterminate subtype. †Patient with ocular melanoma. Melanoma T helper epitopes 1741
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These selected synthetic peptides were then assessed for their
comparative abilities to bind to purified HLA-DR4 molecules
using a solid-state competitive-binding assay (Southwood et al,
1998). The data reported as the dose of peptide capable of
inhibiting 50% of the binding of a reference DR4-binding peptide
(IC50 in nM) are listed in Table 1. Most of the peptides evaluated
bound both HLA-DR4 alleles, albeit over a wide range of
observed IC50 values. The strongest HLA-DR4 (both HLA-
DRB1*0401 and -DRB1*0404) binding peptides for each antigen
tested were gp100615–633 (identical to pmel17622–640) and tyrosin-
ase365–381D, respectively (Table 1). 
Immunoreactivity of CD4+ T cells against predicted
HLA-DR4-binding tumour peptides in HLA-DR4+
melanoma patients 
In a preliminary screen of the immunogenicity of these peptides,
we evaluated the ability of CD4+ T cells isolated directly from the
peripheral blood of 16 HLA-DR4+ patients treated for melanoma
(Table 2) to recognize these putative peptide epitopes using the
IFN-γ ELISPOT assay. Eleven of these individuals (SLM1-
SLM11) were rendered disease-free as a result of surgery and/or
immunotherapy and we hypothesized that their lack of current
disease might, in part, be attributed to circulating anti-melanoma
CD4+ T cells. As indicated in Tables 1 and 3 and Figure 1A, a
number of these disease-free patients displayed detectable frequen-
cies of circulating Th0/Th1-type (i.e. IFN-γ secretors) CD4+ T cells
that recognized a sub-set of the peptides selected for analysis 
(i.e. gp100/pmel176–26, gp100/pmel1744–59, gp 100615–633/pmel17622–640,
tyr.56–70, tyr.156–175, tyr.365–381D and tyr.365–381N). Interestingly, with the
exception of a single HLA-DR4+ patient with ocular melanoma
(SLM12), four additional patients (SLM13-SLM16) with active
stage III or IV disease exhibited minimal or no reactivity to any of
the peptides analysed in IFN-γ ELISPOT assays (Figure 1B).
These same peptides failed to be recognized, or were recognized
extremely poorly by freshly-isolated CD4+ T cells harvested from
a series of 10 normal HLA-DR4+ donors (Figure 1C). 
Immunoreactivity of CD4+ T cells against predicted
HLA-DR4-binding tumour peptides in HLA-DR4+ 
normal donors after in vitro stimulation 
Plastic non-adherent PBMC derived from the HLA-DR4+
normal donors were stimulated with autologous DC that had
been pre-pulsed with a given gp100/pmel17 or tyrosinase pept-
ide identified in Table 1. One week after restimulation of T cells
with identically prepared autologous DC, CD4+ T cells were
purified by immunomagnetic procedures and used as responders
against T2.DR4 target cells pulsed with the candidate DR4-
binding peptides and against an HLA-DR4+/gp100+/ tyrosi-
nase+ melanoma cell line SLM2 in IFN-γ ELISPOT  assays.
Cryopreserved, freshly-isolated (i.e. non-stimulated) CD+ T cells
obtained from each donor were also analysed in these same
assays in order to determine the basal ‘in situ’ level and the
impact of in vitro stimulation on the calculated frequencies of
peptide-specific responder CD4+ T cells in these individuals.
As shown in Tables 1 and 3 and Figure 2, high-frequency
responses (as high as 1/119 against the gp100615–633 (identical to
pmel17622–640 peptide)) were observed from in vitro stimulated
CD4+ T cells against 3/11 gp100/pmel17-and 4/7 tyrosinase-
derived peptides using the IFN-γ ELISPOT assay. On an arbitrary
scale, the gp100/pmel176–26 served as a ‘weak’ immunogen, the
tyrosinase156–175, tyrosinase178–194, and tyrosinase365–381N served as
‘moderate’ immunogens, and the gp100/pmel1744–59, gp100615–633
(identical to pmel17622–640), tyrosinase56–70 and tyrosinase365–381D
served as strong immunogens in both melanoma patients and (in
vitro stimulated) normal donors (Table 1). Two of these peptides
represent previously-defined ‘helper’ T cell epitopes in the
melanoma setting (tyrosinase56–70, gp100/pmel1744–59, Storkus and
Zarour, 2000; Touloukian et al, 2000). The previously defined
Table 3 Significance of differences in epitope reactivity between donor groups evaluated 
P values for differences between groups
Peptide  Patients NED vs Patients NED vs Patients with disease vs
evaluated patients with disease normal donors normal donors 
gp 100/pmel176–26 0.325 0.002 0.031
gp 100/pmel1744–59** 0.036 0.003 0.455 
gp 100/pmel17150–169 0.070 0.152 0.353 
gp 100/pmel17167–189 0.174 0.532 0.353 
gp 100/pmel17283–304 0.178 0.372 0.352 
gp 100/pmel17377–398 0.377 0.480 0.155 
gp 100/pmel17400–421 0.546 0.234 0.234 
gp 100/pmel17506–522 0.546 0.890 0.527 
gp 100/pmel17540–561 0.376 0.685 0.527 
gp 100599–619/pmel17606–626 0.178 0.155 0.527 
gp 100615–633/pmel17622–640 0.043 0.002 0.184 
tyrosinase56–70** 0.026 0.001 0.187 
tyrosinase80–95 0.376 0.602 0.527 
tyrosinase156–175 0.010 0.001 0.485 
tyrosinase178–194 0.618 0.074 0.693 
tyrosinase365–381D 0.132 0.005 0.606 
tyrosinase365–381N 0.687 0.003 0.077 
tyrosinase448–462** 0.262 0.303 0.527 
Two-tailed significance of Figure 1 data analyzed by Mann-Whitney (non-parametric) test. 
P values < 0.05 are underlined. 1742 LS Kierstead et al
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tyrosinase448–462 epitope (Topalain et al, 1996), despite binding
to HLA-DRB1*0401 with moderate ‘affinity’ (Table 1), failed
to be recognized by CD4+ T cells derived from either HLA-
DRB1*0401+ patients or normal donors (Table 1, Figures 1 and
2). As depicted in Figure 2, CD4+ T cells recognizing specific
peptides also recognized the SLM2 melanoma cell line
(columns B and D in each panel) and this recognition was inhib-
ited by inclusion of anti-DR4 mAb in the assay (columns C and
F in each panel). 
CD4+ T cells stimulated in vitro with autologous DC
infected with vaccinia encoding gp100/pmel17 or
tyrosinase or pulsed with melanoma lysates recognize
DR4-presented melanoma peptides 
We next investigated whether autologous HLA-DR4+ DC that
have acquired gp100/pmel17 or tyrosinase as a result of infection
with a recombinant vaccinia virus or via exogenous loading with a
freeze-thaw lysate derived from the allogeneic DR4-negative,
gp100/pmel17+, tyrosinase+ Mel 526 promoted the activation and
expansion of epitope-specific normal donor CD4+ T cells in vitro.
In VAC-gp100/DC stimulated cultures, CD4+ T cells preferen-
tially recognized peptides gp10044–59 and gp100615–633 (identical to
pmel17622–640), and reacted against 2/4 of the HLA-DR4+/gp100+
melanoma cell lines analyzed (Figure 3). CD4+ T cell cultures
stimulated with autologous VAC-tyrosinase infected DC recog-
nized 4 of 6 peptides and 2 of 4 melanoma cell lines evaluated
(Figure 3). CD4+ T cells stimulated with autologous HLA-DR4+
DC pre-pulsed with a lysate derived from the Mel 526 cell line
were cytolytic when tested against HLA-DR4+, gp100/pmel17+,
tyrosinase+ melanoma COLO38 (data not shown). Specific
lysis of COLO38 mediated by this polyspecific T cell population
could be inhibited partially by inclusion of non-radiolabeled
T2.DR4 pre-pulsed with certain peptide epitopes derived from
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Figure 1 Freshly-prepared peripheral blood CD4+ T cell reactivity of HLA-
DR4+ patients with melanoma against gp100/pmel17-and tyrosinase-derived
peptides. Peripheral blood CD4+ T cells were freshly-prepared from HLA-
DR4+ melanoma patients (see Table 2) and normal donors and analyzed for
their reactivity to the algorithm-selected gp 100/pmel17 and tyrosinase
peptides using 20 h IFN-γ ELISPOT assays. Depicted are the results from 11
melanoma patients currently free of disease (panel A), 5 melanoma patients
with active disease (panel B) and 10 normal donors (panel C). Data depicted
represent the mean of triplicate determinations from which the mean of CD4+
T cell responses against the control T2.DR4 (i.e. no peptide) presenting cell
line has been subtracted (in all cases, the mean of this background control
value was ≤ 6 spots). To determine positive responsiveness as summarized
in Table 1, patient mean data (spots per 100,000 CD4+ T cells) for a given
peptide had to exceed the mean + 3 S.D. of the corresponding spot number
obtained from the 10 normal donors. The normal mean + 3 S.D. values for
the individual peptides were: gp1006–26 (1.4); gp10044–59 (3.7); gp100150–169
(1.8); gp100167–179 (1.8); gp100283–304 (1.4); gp100377–398 (1.5); gp100400–421
(1.6); gp100506–522 (1.5); gp100540–561 (1.4); gp100599–619 (1.4); gp100615–633
(3.9); tyr.56–70 (4.9); tyr.80–95 (1.0); tyr.156–175 (1.0); tyr.178–194 (1.3); tyr.365–381D
(5.3); tyr.365–381N (1.3); tyr.448–462 (1.0) 
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Figure 2 Reactivity of HLA-DR4+ normal donor CD4+ T cells after in vitro
sensitization with gp100/pmel17-and tyrosinase-derived peptides. HLA-
DR4+ normal donor peripheral blood CD4+ T cells were stimulated with
autologous monocyte-derived DC pre-pulsed with the indicated
gp100/pmel17 and tyrosinase peptides. After an additional restimulation with
identically prepared DC one week later (i.e. day 7 of culture), the resultant
purified CD4+ T cell populations were analyzed for peptide-specific reactivity
in 20 h IFN-γ ELISPOT assays (i.e. on day 14–17 of culture). Individual
target groups are indicated. Data are representative for 1 of 10 normal
donors evaluated and are qualitatively summarized in Table 1 Melanoma T helper epitopes 1743
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gp100/pmel17 and tyrosinase, with the gp100615–633 and tyrosi-
nase56–70 peptides proving to be most effective (data not shown).
Overall, this suggests that immunogenic core epitope(s) resident
within each of these biologically-active, synthetic sequences is
naturally processed and presented by antigen-loaded host DC and
by HLA-DR4+ melanomas that constitutively express the relevant
antigens. 
DISCUSSION 
Using HLA-DR4+ patient’s PBMC, a peptide-binding algorithm,
and a high-sensitivity IFN-γ ELISPOT assay, we have identified
three novel, non-overlapping epitopes derived from the
gp100/pmel17 and tyrosinase melanoma-associated antigens
(MAA) that are functionally recognized by Th1-type CD4+ T
cells. In addition, two of three previously identified CD4+
epitopes derived from gp100/pmel17 and tyrosinase
(gp100/pmel1744–59 and tyrosinase56–70 but not tyrosinase448–462)
were also confirmed in these analyses (Topalian et al, 1996;
Storkus and Zarour, 2000; Touloukian et al, 2000). Overall, 7/18
peptides chosen for evaluation (based on the algorithm analysis)
appeared to promote Th1-type responses from purified CD4+ T
cells obtained from melanoma patients. CD4+ T cells from normal
HLA-DR4+ donors were poorly reactive against epitopes and,
with the exception of the dramatic anti-tyrosinase responses noted
for a single patient with ocular melanoma (i.e. SLM12), CD4+ T
cells from patients with active disease also tended to display
muted peptide-specific responses. In marked contrast, CD4+ T
cells isolated from the PBMC of patients that have been effectively
treated in the clinic and that remain disease-free, displayed signif-
icantly elevated responses to a number of these putative epitopes.
This suggests that long-term ‘memory’ CD4+ T cells may circu-
late at high frequency in the periphery of these ‘protected’
patients. 
Alternatively or additionally, the T cell repertoires of these
patients may have been periodically restimulated (by clinically
undetectable, recurrent micrometastatic disease) by either class II+
tumours themselves or via ‘cross-presentation’ by tumour-associa-
ted antigen presenting cells (Ossendorp et al, 1998; Albert et al,
1998; Lotze et al, 1997). Our data provided in Figure 3 and support
the ability of CD4+ T cells to recognize processed epitopes ‘cross-
presented’ by autologous DC. In particular, novel epitopes within
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Figure 3 DC infected with rVac-gp100 (VAC-gp100) or rVac-tyrosinase (VAC-Tyr.) elicit peptide-specific CD4+ T cells in vitro. Immature DC were generated in
vitro from a normal HLA-DR4+ (DRB1*0401 +) donor and infected with the indicated recombinant vaccinia viruses at an MOI of 50 as previously described (18)
and then used to stimulate autologous CD4+ T cells at a responder-to-stimulator ratio of 20:1. After being restimulated with identically prepared DC on day 7 of
culture, CD4+ T cells were harvested and evaluated for their reactivity against peptide-pulsed T2.DR4 target cells or a series of melanoma cell lines in 20 h IFN-
γ ELISPOT assays one week later (open symbol). The mean of background T cell responses against the T2.DR4 target (without peptide) have been subtracted
in all cases of peptide testing, but were 23 spots and 16 spots per 100,000 CD4+ T cells in the Vacc-gp100 and Vacc-tyrosinase cultures, respectively. T cells
responses to melanoma target cell lines were not corrected and represent actual spot numbers. Peptide CS is an HLA-DR4-presented epitope derived from the
malarial circumsporozooite protein that serves as a negative biological control. Melanoma cell line phenotypes are as follows: SLM2 is HLA-DR4+,
gp100/pmel17+, tyrosinase+; M21 is HLA-DRdim+, gp100/pmel17+, tyrosinase+; COLO38 is HLA-DR4+, gp100/pmel17+, tyrosinase+; and Mel1011 is HLA-
DR4+, gp100/pmel17+/–, tyrosinase+ (see Materials and Methods). The DR4-restricted nature of T cell reactivity was demonstrated by addition of blocking anti-
HLA-DR4 mAb 359-13F10 (filled symbol). Data represent the mean +/– SD of triplicate determinations from 1 of 3 donors evaluated. All donors displayed
similar reactivity patterns. 1744 LS Kierstead et al
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the gp100615–633, tyrosinase156–175 and tyrosinase365–381D/N peptides
appeared to be naturally presented by relevant antigen cDNA trans-
duced DC (while those for gp1006–26 and tyrosinase178–194 were not).
Such cognate recognition of cross-presented epitopes in situ may
promote the function or durability of infiltrating CD8+ T cells by
enhancing CTL cytolytic activity or increasing target cell recogni-
tion via upregulation of MHC class I molecule expression (i.e. IFN-
γ ) and by protecting T cells against tumour-induced apoptosis
(Lorenz et al, 1997). 
Of the three novel, non-overlapping epitopes defined in this
study, one was derived from the gp100/pmel17 protein (gp
100615–633 (identical to pmel17622–640)) and two were derived from
the tyrosinase protein (tyrosinase156–175 and tyrosinase365–381D (over-
laps with tyrosinase365–381N)). While the gp100/pmel176–26 peptide
was reacted against by CD4+ T cells obtained from melanoma
patients free of disease and normal donors stimulated with
peptides in vitro (Table 1), these responses were very modest and
were not observed in cultures stimulated by Vac-gp100-infected
autologous DC (Figure 3). This could reflect the differential
processing of this gp100 epitope by melanomas versus transduced
DC, given variance in processing observed amongst antigen-
presenting cells (Vidard et al, 1992), or it could reflect T cell cross-
reactivity against another naturally-processed sequence expressed in
the melanoma setting. Given these uncertainties, we do not classify
this peptide as containing a naturally-processed epitope at this time. 
Interestingly, one of the HLA-DR4 presented tyrosinase
epitopes (i.e. tyrosinase365–381) encompasses a glycosylation site
known to be post-translationally-modified in melanoma cells.
Thus, the genomically-encoded tyrosinase contains an asparagine
(N, single letter designation) residue at position 370 that is modi-
fied into an aspartic acid (D, single letter designation) as a result of
enzymatic processing. Skipper et al (1996) have previously
demonstrated that this modification yields the naturally-processed
and HLA-A2-presented tyrosinase368–376 (YMDGTMSQV)
epitope. We have now similarly shown that a ‘post-translationally
modified’ tyrosinase365–381D, but not the genomically-encoded
tyrosinase365–381N peptide, serves as a strong HLA-DR4-presented
immunogen recognized by melanoma-reactive CD4+ T cells. The
observed enhanced immunoreactivity of the tyrosinase365–381D
peptide can be attributed, in part, to its approximately 100-fold
better binding ‘affinity’ to HLA-DRB1*0401 (vs the tyrosin-
ase365–381N peptide, Table 1). The lack of cross-reactivity of
responder CD4+ T cells against these two epitopes, however, may
also argue for non-overlapping peptide-specific T cell repertoires. 
The immunogenic gp100/pmel17 and tyrosinase epitopes iden-
tified in this study are presented by HLA-DR4, which is expressed
by 18–20% of the population afflicted with melanoma (Gjertson
and Lee, 1998). The clinical utility of these sequences would be
enhanced greatly if they could be presented in the context of addi-
tional HLA-DR alleles to melanoma-reactive CD4+ T cells. Our
preliminary analysis suggests that a number of these epitopes bind
to a broad range of MHC class II alleles (data not shown). For
instance, the gp100/pmel1744–59 peptide binds to (at least) the
HLA-DR1, -DR3, -DR4, -DR7, -DR13 and -DRw53 (i.e.
-DRB4*0401) alleles that cover in excess of one-half of the
American population (Gjertson and Lee, 1998). If naturally
presented by these non-HLA-DR4 alleles, these pan-DR binding
peptides may prove immunogenic to a broad range of patients, a
possibility that we are currently evaluating. 
While we have identified a series of biologically-active epitopes
in this study, we have little conclusive data (save for confirmation of
the gp100/pmel1744–59 sequence, recently identified as a natural
epitope (Storkus and Zarour, 2000; Touloukian et al, 2001) to
support that these sequences are ‘naturally-presented’ in the exact
format as tested. We are currently performing mass spectrometric
analyses of peptides derived from affinity-purified HLA-DR4
complexes obtained from MHC class II+ melanoma cell lines in
order to determine a series of natural tumour-processed ‘minimal
core epitopes’. From a practical perspective however, the identifica-
tion of a ‘minimal core epitope’ may be a subordinate issue in the
context of the potential clinical applications of these peptides, which
include immune monitoring and vaccine construction. Long
peptides (i.e. 12–16 amino acids) containing a core 9-mer epitope
have been previously shown to elicit protective immunity mediated
by CD8+ T cells in the in vivo vaccine setting (Kast et al, 1993) or in
vitro after direct binding of peptide to the MHC molecule (Kittlesen
et al, 1998 and unpublished observations). Similar mechanisms
would likely allow for ‘optimal’ loading of HLA-DR complexes
with relevant epitopes that are typically not as constrained for length
as are MHC class I-presented peptides (Falk et al, 1994). This might
be best analysed in preclinical in vivo systems such as the DR-IE
transgenic mouse and SCID-Hu vaccine models that have been
recently used to corroborate or define the gp10044–59 or gp100231–243
epitopes (Touloukian et al, 2000; Cochlovius et al, 2000). The latter
model (Cochlovius et al, 2000) in particular, could provide strong
support for the clinical utility of vaccines incorporating HLA-DR
presented epitopes since DC-peptide vaccines may inhibit the
growth of melanoma cell lines expressing the relevant antigen (i.e.,
from which the peptide derived) in situ. 
A potentially added benefit to the clinical use of certain of the
identified gp100/pmel17 and tyrosinase peptides is that they
contain embedded CTL epitopes (Table 1). Hence, a single
synthetic peptide may yield both CD4+ and CD8+ T cell
recognized determinants when appropriately processed in situ, by
at least some patients (bearing the appropriate MHC class I alleles
for CTL epitope presentation). Such combination vaccines
containing ‘helper’ T and CTL epitopes may prove particularly
therapeutic (Ranieri et al, 2000). 
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